The global multiple sclerosis therapies (IVA) industry garnered $22.99 million in 2018, and is estimated to reach $28.00 million by 2026, registering a CAGR of 2.5% from 2019 to 2026.
Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/1438
Rise in number of pipeline drugs, increase in patient population, and surge in number of patient assistance programs (PAPs) fuel the growth of the global multiple sclerosis therapies market. However, unspecified disease etiology restrains the market growth. On the other hand, emergence of disease-modifying drugs and utilization of off-label drugs create new opportunities in the coming years.
According to the National MS society’s National Medical Advisory Committee, during the COVID-19 pandemic, the decision to opt for disease modifying therapies should be collaboratively made by the person with MS and his healthcare provider.
The National MS society has recommended that the CDC guidelines should be followed by the people with MS by considering the risk from Covid-19 pandemic. People with MS can continue DMTs with the instructions from their healthcare provider.
The medicinal and other requirements for therapies may not be fulfilled due to shortage of medicines or delay from disturbed supply chain.
Inquiry for Buying Report @ https://www.alliedmarketresearch.com/purchase-enquiry/1438
Leading market players-
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
The Immunosuppressant segment to maintain its lead status-
Based on type, the immunosuppressant segment accounted for nearly two-thirds of the total share of the global multiple sclerosis therapies market in 2018, and is expected to maintain its lead status in terms of revenue throughout the forecast period. In addition, the segment is anticipated to manifest the fastest CAGR of 2.8% from 2019 to 2026. This is due to their beneficial effects for patients suffering from relapsing-remitting multiple sclerosis (RRMS). The immunosuppressant suppresses the autoimmune attack in the patient’s body and prevents relapses.
The oral segment to maintain its leadership position during the forecast period-
Based on route of administration, the oral segment contributed to the highest market share with more than two-fifths of the global multiple sclerosis therapies market share in 2018, and is estimated to maintain its leadership position during the forecast period. Furthermore, the segment is estimated to generate the fastest CAGR of 2.8% from 2019 to 2026. This is due to significant therapeutic advances in the new orally administered drugs approved for the MS treatment.
North America to maintain its dominant by 2026-
Based on region, North America, accounted for the highest share based on revenue, holding for nearly two-fifths of the total share of the global multiple sclerosis therapies market in 2018, owing to rise in U.S. FDA approvals for medications used in the treatment of MS and improved healthcare system in this region. However, LAMEA is estimated to portray the fastest CAGR of 3.1% from 2019 to 2026, owing to the high prevalence of MS in the Middle East countries.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.